![Nancy Miller-Rich](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Nancy Miller-Rich
Directeur/Bestuurslid bij
ALDEYRA THERAPEUTICS, INC.
Vermogen: 1 420 $ op 31-07-2026
Profiel
Nancy Miller-Rich is the founder of Miller-Rich Associates LLC, founded in 2017, where the title held is Chief Executive Officer.
Ms. Miller-Rich is the founder of Ten63 Therapeutics, Inc., founded in 2020, with no titles listed.
Current jobs include Executive Chairman at MedMelior, Inc.; Independent Director at Attralus, Inc. since 2020; Director at Global Alliance for TB Drug Development since 2018; Independent Director at Aldeyra Therapeutics, Inc. since 2020; Independent Director at 4D Molecular Therapeutics, Inc. since 2020; and Director at Helio Vision, Inc. Former jobs include Chairman at BioTheryX, Inc. from 2022 to 2023; Independent Director at Intercept Pharmaceuticals, Inc. from 2018 to 2023; Independent Non-Executive Director at UDG Healthcare Ltd. (Dublin) from 2016 to 2020; Independent Director at Kadmon Holdings, Inc. from 2020 to 2021; SVP-Global Human Health Business Development at Merck & Co., Inc. from 2013 to 2017; and SVP-Global Human Health Business Development at Schering-Plough Corp.
USA. from 2013 to 2017.
Education includes an undergraduate degree from Ithaca College conferred in 1981.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 09-06-2026 | 922 ( 0% ) | 1 420 $ | 31-07-2026 | |
| 17-06-2026 | 0 ( -.--% ) | - $ | 31-07-2026 |
Actieve functies van Nancy Miller-Rich
| Bedrijven | Functie | Begin |
|---|---|---|
| ALDEYRA THERAPEUTICS, INC. | Directeur/Bestuurslid | 13-01-2020 |
| 4D MOLECULAR THERAPEUTICS, INC. | Directeur/Bestuurslid | 18-11-2020 |
Global Alliance for TB Drug Development
 Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Develops tuberculosis drugs | Directeur/Bestuurslid | 06-03-2018 |
Altum Pharmaceuticals, Inc.
 Altum Pharmaceuticals, Inc. Pharmaceuticals: GenericHealth Technology Engage in business of developing therapeutics for women | Voorzitter | - |
Attralus, Inc.
 Attralus, Inc. Pharmaceuticals: MajorHealth Technology Develops novel pan-amyloid removal therapeutics | Directeur/Bestuurslid | 01-07-2020 |
Miller-Rich Associates LLC | Algemeen Directeur | 01-01-2017 |
Helio Vision, Inc.
 Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Develop a therapy for fibro proliferative disorders that lead to abnormal scarring and blindness after retina surgery | Directeur/Bestuurslid | - |
Eerdere bekende functies van Nancy Miller-Rich
| Bedrijven | Functie | Einde |
|---|---|---|
| INTERCEPT PHARMACEUTICALS, INC. | Directeur/Bestuurslid | 08-11-2023 |
BioTheryX, Inc.
 BioTheryX, Inc. Packaged SoftwareTechnology Services Operates as a biopharmaceutical company that develops protein degradation platform | Voorzitter | 01-04-2023 |
| ░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Opleiding van Nancy Miller-Rich
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
92
Eerstegraads connecties
15
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 15 |
|---|---|
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Manufactures and sells pharmaceutical & health care products | Health Technology |
Global Alliance for TB Drug Development
Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Develops tuberculosis drugs | Health Technology |
Aldeyra Therapeutics, Inc.
 Aldeyra Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics for eye diseases | Health Technology |
Intercept Pharmaceuticals, Inc.
 Intercept Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for the treatment of chronic fibrotic and metabolic diseases | Health Technology |
BioTheryX, Inc.
BioTheryX, Inc. Packaged SoftwareTechnology Services Operates as a biopharmaceutical company that develops protein degradation platform | Technology Services |
Kadmon Holdings, Inc.
 Kadmon Holdings, Inc. BiotechnologyHealth Technology Discovers, develops and delivers transformative therapies for unmet medical needs | Health Technology |
UDG Healthcare Ltd. (Dublin)
 UDG Healthcare Ltd. (Dublin) Miscellaneous Commercial ServicesCommercial Services Provides healthcare advisory, communications, commercial, clinical and packaging services | Commercial Services |
Ithaca College
 Ithaca College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
4D Molecular Therapeutics, Inc.
 4D Molecular Therapeutics, Inc. BiotechnologyHealth Technology Designs, develops and commercializes transformative gene therapeutic products for serious unmet medical conditions | Health Technology |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Develop a therapy for fibro proliferative disorders that lead to abnormal scarring and blindness after retina surgery | Health Technology |
Altum Pharmaceuticals, Inc.
Altum Pharmaceuticals, Inc. Pharmaceuticals: GenericHealth Technology Engage in business of developing therapeutics for women | Health Technology |
TEN63 Therapeutics
 TEN63 Therapeutics Packaged SoftwareTechnology Services Develops AI platform for drug discovery | Technology Services |
Attralus, Inc.
Attralus, Inc. Pharmaceuticals: MajorHealth Technology Develops novel pan-amyloid removal therapeutics | Health Technology |
Miller-Rich Associates LLC |
